Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05828511 · ClinicalTrials.gov registry record · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A Phase 1 study of Multiple Myeloma, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
- 20
- Study locations
NCT05828511 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 149 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05828511, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: * In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2. * In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug. * In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM. The study is looking at several research questions, including: * What side effects may happen from taking linvoseltamab? * What the right dosing regimen is for linvoseltamab? * How many participants treated with linvoseltamab have improvement of their disease and for how long? * The effects of linvoseltamab study treatment before and after transplant * How much linvoseltamab is in the blood at different times? * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Conditions Studied
Interventions
- DRUG Linvoseltamab
Study Locations (20)
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- Perlmutter Cancer Center - New York
- Columbia University _ New York Presbyterian - New York
- Stony Brook University Hospital - Stony Brook
Other
- CHU De Lille - Lille
- Centre Hospitalier Universitaire (CHU) Montpellier - Montpellier
- Hopital Saint Louis - Paris
- University Hospitals Pitie Salpetriere - Charles Foix - Paris
California
- University of California Los Angeles (UCLA) - Los Angeles
- UC Irvine Health - Orange
North Carolina
- Levine Cancer Institute - Charlotte
- Duke University Health System (DUHS) - Durham
Île-de-France Region
- Hopital Prive d'Antony - Antony
- Hopital Necker - Paris
Colorado
- Colorado Blood Cancer Institute/SCRI - Denver
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2035-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05828511
The ClinicalTrials.gov registry entry for NCT05828511 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Linvoseltamab is the first listed.
NCT05828511 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Other, California.
Frequently Asked Questions
What is clinical trial NCT05828511 about?
NCT05828511 is a clinical study titled "A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment". This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for a...
What is the current status of trial NCT05828511?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2023-12-19. Estimated completion is 2035-11-02.
What conditions does trial NCT05828511 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05828511?
The interventions under investigation include: Linvoseltamab (DRUG).
Who is sponsoring clinical trial NCT05828511?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05828511 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.